No Yes Ok

Archive

« Older Entries Newer Entries »

LSP’s portfolio company argenx and AbbVie to collaborate on ARGX-115 against novel immuno-oncology target Thursday, April 21st, 2016
Amsterdam, the Netherlands – 21 April 2016 – AbbVie (NYSE: ABBV), a global biopharmaceutical company, and LSP’s portfolio company argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focu [...]
LSP co-leads Series A financing of G-Therapeutics that raises EUR 36 mln to develop its neuro-stimulation therapy for spinal cord injury Tuesday, April 19th, 2016
Amsterdam, the Netherlands – 19 April 2016 – G-Therapeutics announces today that it has raised EUR 36 million to develop its novel neuro-stimulation therapy for people with spinal cord injuries (SCI). G-Therapeuti [...]
Merus to Present Interim Clinical Data from Ongoing Phase 1/2 Clinical Trial of its Lead Bispecific Antibody Candidate, MCLA-128, at the American Associati... Friday, April 15th, 2016
MCLA-128 Shows Favorable Safety Profile and Early Signs of Anti-Tumor Activity in Patients with Advanced Solid Tumors   UTRECHT, The Netherlands, April 15, 2016 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stag [...]
New topinstitute for cancer launched in The Netherlands Wednesday, April 13th, 2016
The Netherlands has a very strong science base in for example oncology, but the step from science to developing new therapies and diagnostics is still not an easy one.   In view of LSP’s commitment to help [...]
Kiadis Pharma proposes Robert Soiffer and Berndt Modig as its new Supervisory Board members Thursday, April 7th, 2016
Amsterdam, The Netherlands, April 7, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-ce [...]
Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR101™ Monday, April 4th, 2016
Significant increase in Overall Survival and reduction in Transplant Related Mortality observed in comparison to a historical control group Zero patients developed grade III-IV acute Graft-versus-Host-Diseas [...]
Curetis to Launch CE-IVD Unyvero Blood Culture Application Cartridge at ECCMID 2016 Thursday, March 24th, 2016
- Successful completion of CE Performance Evaluation Study - Covers 103 diagnostic targets with 87 pathogens and 16 resistance markers   Amsterdam, the Netherlands and Holzgerlingen, Germany, March 23, 20 [...]
Probiodrug Appoints Mark Booth as Chief Business Officer Wednesday, March 23rd, 2016
Expands Management Board with Senior Hire   HALLE/SAALE, Germany, 23 March 2016 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer [...]
Bio€quity 2016 Tuesday, March 15th, 2016
LSP is a sponsor of the Bio€quity Europe 2016 in Copenhagen, Denmark. To obtain further information or to register please follow this link. [...]
ETheRNA, een spin-off van de VUB, werkt aan een immuuntherapie met een 'drievoudige boost' Tuesday, March 15th, 2016
ETheRNA, een spin-off van de VUB, werkt aan een immuuntherapie met een 'drievoudige boost'. Dirk Reyn, de stichter van het vroegere Movetis, zet zijn schouders onder het bedrijf.   ETheRNA haalt 24 mi [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

« Older Entries Newer Entries »

LSP’s portfolio company argenx and AbbVie to collaborate on ARGX-115 against novel immuno-oncology target Thursday, April 21st, 2016
Amsterdam, the Netherlands – 21 April 2016 – AbbVie (NYSE: ABBV), a global biopharmaceutical company, and LSP’s portfolio company argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focu [...]
LSP co-leads Series A financing of G-Therapeutics that raises EUR 36 mln to develop its neuro-stimulation therapy for spinal cord injury Tuesday, April 19th, 2016
Amsterdam, the Netherlands – 19 April 2016 – G-Therapeutics announces today that it has raised EUR 36 million to develop its novel neuro-stimulation therapy for people with spinal cord injuries (SCI). G-Therapeuti [...]
Merus to Present Interim Clinical Data from Ongoing Phase 1/2 Clinical Trial of its Lead Bispecific Antibody Candidate, MCLA-128, at the American Associa... Friday, April 15th, 2016
MCLA-128 Shows Favorable Safety Profile and Early Signs of Anti-Tumor Activity in Patients with Advanced Solid Tumors   UTRECHT, The Netherlands, April 15, 2016 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stag [...]
New topinstitute for cancer launched in The Netherlands Wednesday, April 13th, 2016
The Netherlands has a very strong science base in for example oncology, but the step from science to developing new therapies and diagnostics is still not an easy one.   In view of LSP’s commitment to help [...]
Kiadis Pharma proposes Robert Soiffer and Berndt Modig as its new Supervisory Board members Thursday, April 7th, 2016
Amsterdam, The Netherlands, April 7, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-ce [...]
Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR101™ Monday, April 4th, 2016
Significant increase in Overall Survival and reduction in Transplant Related Mortality observed in comparison to a historical control group Zero patients developed grade III-IV acute Graft-versus-Host-Diseas [...]
Curetis to Launch CE-IVD Unyvero Blood Culture Application Cartridge at ECCMID 2016 Thursday, March 24th, 2016
- Successful completion of CE Performance Evaluation Study - Covers 103 diagnostic targets with 87 pathogens and 16 resistance markers   Amsterdam, the Netherlands and Holzgerlingen, Germany, March 23, 20 [...]
Probiodrug Appoints Mark Booth as Chief Business Officer Wednesday, March 23rd, 2016
Expands Management Board with Senior Hire   HALLE/SAALE, Germany, 23 March 2016 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer [...]
Bio€quity 2016 Tuesday, March 15th, 2016
LSP is a sponsor of the Bio€quity Europe 2016 in Copenhagen, Denmark. To obtain further information or to register please follow this link. [...]
ETheRNA, een spin-off van de VUB, werkt aan een immuuntherapie met een 'drievoudige boost' Tuesday, March 15th, 2016
ETheRNA, een spin-off van de VUB, werkt aan een immuuntherapie met een 'drievoudige boost'. Dirk Reyn, de stichter van het vroegere Movetis, zet zijn schouders onder het bedrijf.   ETheRNA haalt 24 mi [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund